Myriad Genetics, PATHOMIQ enter agreement for usage of AI platform for prostate cancer

Myriad Genetics and PATHOMIQ have entered into an agreement to allow Myriad to exclusively license PATHOMIQ’s AI-enabled diagnostic platform for prostate cancer, PATHOMIQ_PRAD, in the US.¹

The PATHOMIQ_PRAD solution has been assessed across various settings in prostate cancer.

This addition expands Myriad’s existing portfolio of oncology solutions.

PATHOMIQ_PRAD is designed to assess the risk of biochemical recurrence and metastasis by analyzing digitized H&E whole slide images from tissue collected at radical prostatectomy.² The AI platform then provides a risk profile report within 1 day of receiving the patients’ sample.

“I am excited to have co-developed, with the PATHOMIQ team, the PATHOMIQ-PRAD AI model for prostate cancer treatment response prediction and identification of high-risk prostate cancer patients who will experience early metastasis post-radical prostatectomy,” said Ashutosh K. Tewari, Chairman of the Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mt Sinai in New York, New York, in the news release.¹ “The AI model has achieved high prediction accuracy and outperformed some of the currently used markers in both Caucasian and African American patient cohorts for a much-improved patient outcome.”

Data on PATHOMIQ_PRAD

The PATHOMIQ_PRAD solution has been assessed across various settings in prostate cancer.

Among patients with intermediate-risk prostate cancer, the PATHOMIQ_PRAD solution was significantly better at predicting biochemical recurrence and ranking risk of metastasis compared with Gleason grade, TNM staging, and genomic tools.³ Among patients with Gleason grade 3+4, a high PATHOMIQ score was associated with a higher risk of biochemical recurrence compared with low PATHOMIQ scores (HR, 3.3; 95% CI, 1.44 – 7.56; P < .005).

The test also demonstrated the ability to identify patients with non-metastatic castration-resistant prostate cancer who are high risk of progressing to metastatic disease.⁴ Among those with high PATHOMIQ scores, patients who received apalutamide plus androgen deprivation therapy (ADT) demonstrated a significant improvement in metastasis-free survival compared with patients who received placebo plus ADT.

Additional details on the collaboration

The addition of PATHOMIQ_PRAD is complementary to the company’s exisiting combined germline and comprehensive tumor profiling solution, Prolaris Prostate Cancer Prognostic Test. According to Myriad, the combination of tests allows the company to “provide urologists and radiation oncologists with molecular and AI-powered testing solutions to inform decisions both before treatment at the time of biopsy for active surveillance and following surgery or radiation treatment.”

“Along with our Prolaris Prostate Cancer Prognostic Test, we are pleased to leverage PATHOMIQ’s prognostic and predictive capabilities across different phases of the patient journey in prostate cancer,” said George Daneker, Jr., MD, president and Chief Clinical Officer of Oncology at Myriad Genetics, in the news release.¹ “Having both genetic and morphologic insights at the time of biopsy combined with the enhanced ability to predict disease recurrence after initial therapy can lead to more informed treatment decisions and enhance the potential for better patient outcomes. This partnership is the latest step in the strategic expansion of Myriad’s oncology portfolio. Our molecular science expertise, combined with the latest in machine learning and AI, will uniquely position Myriad to deliver higher-quality insights for patients and clinicians in the fight against cancer.”

According to Myraid, the addition of PATHOMIQ_PRAD is expected to accelerate the timeline for meeting Simon level 1 evidence for both the Prolaris and PATHOMIQ_PRAD tests. The company is planning to launch its first AI-driven prostate cancer clinical test later this year, they reported.

References

1. Myriad Genetics partners with PATHOMIQ to add artificial intelligence technology platform to its oncology portfolio. News release. Myriad Genetics. February 24, 2025. Accessed February 25, 2025. https://investor.myriad.com/news-releases/news-release-detail/26026/

2. PATHOMIQ_PRAD. PATHOMIQ. Accessed February 25, 2025. https://pathomiq.com/products/

3. Nair S, Muhammad H, Jain P, et al. A novel, AI-generated morphologic biomarker to predict prostate cancer recurrence in patients with intermediate risk of progression. J Clin Oncol. 2023;41. (suppl 16) Abstract e17097. doi:10.1200/JCO.2023.41.16_suppl.e17097

4. Mobadersany P, Tian SK, Yip SSF, et al. AI-enabled analysis of H&E-stained prostate cancer tissue images: Assessing risk for metastasis prior to apalutamide (APA) treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC). J Clin Oncol. 2023;41. (suppl 16) Abstract 5027. doi:10.1200/JCO.2023.41.16_suppl.5027